Results 111 to 120 of about 20,312 (245)
Intravesical therapy for recurrent urinary tract infection: a systematic review and meta‐analysis
BJU International, Volume 138, Issue 1, Page 33-44, July 2026.Objective To undertake a systematic review and meta‐analysis to evaluate the efficacy, safety, and clinical applicability of intravesical instillations for preventing recurrent urinary tract infections (rUTIs). Methods PubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus, and Web of Science were searched from January 2000 to April 2025 for randomised and ...
Matthew Kwon +3 more
wiley +1 more source
Biotechnology Journal, Volume 21, Issue 6, June 2026.Graphical Abstract and Lay Summary This study presents the first systematic development and analytical validation of an automated fluorescence‐ and image‐based viable‐cell counting method for fecal microbiota transplantation (FMT) drug products in accordance with ICH Q2(R2).
Timon Lang +4 more
wiley +1 more source
Современные подходы к иммунотерапии инфекции Clostridioides difficile
Clostridioides difficile is a leading cause of diarrhea and pseudomembranous colitis associated with antibiotic therapy. Hypervirulent strains of C. difficile, such as ribotype 027, have high mortality rates. Recurrent C. difficile infection is extremely
V. V. Makarov +3 more
core +1 more source
Clinical Case Reports, Volume 14, Issue 6, June 2026.ABSTRACT Persistent diarrhea during anticancer therapy may not be attributable to anticancer agents. Our patient presented with diarrhea during lenvatinib–pembrolizumab therapy, likely caused by lansoprazole‐induced microscopic colitis. Even when symptoms closely resemble anticancer drug or immune‐related colitis, drug‐induced colitis due to ...
Shinichi Maruyama +6 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1514-1521, June 2026.The U.S. Food and Drug Administration (FDA) used an Active Postmarket Risk Identification and Analysis (ARIA) system to address a safety issue (serious infection) identified during clinical review of an application to market ustekinumab as a treatment for Crohn's disease (CD). FDA used an active‐comparator new‐user cohort design, data from six Sentinel
Joel L. Weissfeld +9 more
wiley +1 more source
Lactoferrin-Loaded Alginate Microparticles to Target Clostridioides difficile Infection
, 2019 Some forms of bovine lactoferrin (bLf) are effective in delaying Clostridioides difficile growth and preventing toxin production. However, therapeutic use of bLf may be limited by protein stability issues.
Śpiewak, Klaudyna +7 more
core +1 more source
Hear my voice: involving patients in Clostridioides difficile infection research
, 2023 Clostridioides difficile infection (CDI) is a major cause of hospital-acquired diarrhoea affecting considerable numbers of people each year. CDI can cause a debilitating illness which impacts on people and their families and the economic resources of ...
John Heritage (16483939) +6 more
core +1 more source
MEAT PIES: Mammalian Meat Allergy in Patients Investigated for Gastrointestinal Symptoms
JGH Open, Volume 10, Issue 6, June 2026.ABSTRACT Background Alpha‐gal syndrome (AGS), an IgE‐mediated allergy to galactose‐α‐1,3‐galactose acquired via tick bites, often presents with a delayed gastrointestinal (GI) phenotype without anaphylaxis. We evaluated a local diagnostic guideline in a Far North Queensland gastroenterology outpatient clinic.
Elias Bitzer +2 more
wiley +1 more source
Background.Antimicrobial susceptibility testing (AST) is not routinely performed for Clostridioides difficile and data evaluating minimum inhibitory concentrations (MICs) are limited.
core +2 more sources
Possible contribution of shoes to clostridioides difficile transmission within hospitals
, 2020 Clostridioides difficile remains the most common cause of healthcare-associated intestinal infection. Hospitalized patients aged >65 years and receiving antibiotic therapy are the population most at risk of C. difficile infection (CDI)
Blazevic, Ines +5 more
core +1 more source